Senderowicz Adrian sold $194K of PBYI
Senderowicz Adrian sold 27,000 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 ($0.19M total) on 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 27,000 shares at $7.1967/share, totaling $194,310.90, under a 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but this specific disclosure lacks any fundamental catalyst in the provided text.
What to watch
The filing does not state any change in business fundamentals, and the post-transaction holdings are not reduced to zero, limiting interpretability.
Background
The article is an SEC Form 4 insider transaction disclosure for PUMA Biotechnology, Inc. (PBYI).
Ticker impact
SEC Form 4 shows director Adrian Senderowicz sold 27,000 PBYI shares in an open-market transaction under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
The filing is a routine 10b5-1 open-market sale by a director, with no accompanying guidance, deal, or regulatory/operational catalyst in the text.
Market effects
No sector read-through provided; this is company-specific insider transaction data only.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect diversification or liquidity needs rather than bearish expectations.
Key entities
- issuerPUMA BIOTECHNOLOGY, INC.
Subject of the Form 4 insider transaction disclosure.
- insiderAdrian Senderowicz
Director who sold 27,000 shares under a 10b5-1 plan.
